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Toward a Better Understanding of...
Development and Characterization of 
TREM2 HEK Cells as a Model for Alzheimer's 
with TREM2 mAb Agonists
Nikash Shankar
Mentor: Jason Ulrich
Alzheimer’s disease is a neurological disorder that is characterized by two major 
hallmarks—the extracellular aggregation of beta-amyloid (Aβ) peptides to form Aβ 
plaques and the hyperphosphorylation of microtubule-binding protein tau to form 
neurofibrillary tangles (NFTs). The R47H loss-of-function variant in TREM2, a microglial 
transmembrane surface receptor that is important for cell survival and proliferation, 
was found to strongly increase the risk for developing Alzheimer’s. Individuals with the 
R47H TREM2 variant were also found to have reduced microgliosis around Aβ plaques. 
These findings suggest that TREM2 induced microgliosis could protect against the 
aforementioned neuritic dystrophy and NFT formation, thereby slowing the progression 
of the disease. However, the specific effects of TREM2 activation still remain unclear. This 
study sought to establish a HEK cell line that expressed a functional TREM2-DAP12 cell 
membrane reporter to characterize its efficacy as a model for Alzheimer’s, using TREM2 
mAb agonists.
After establishing a puromycin kill curve to select 2 µg/mL of antibiotic as an optimal 
concentration for cell selection, TREM2-DAP12 transfected cells were tested at this dose 
to see whether they had been successfully transfected. High survival rates confirmed that 
the HEK cells had taken up the plasmid construct. A subsequent qPCR on the TREM2-
DAP12 transfected cells and control HEK cells revealed that the transfected cells were 
able to amplify both TREM2 and DAP12 genes, indicating that they readily expressed 
both genes, in addition to the puromycin resistance gene. It was then discovered via 
fluorescence microscopy that hamster mAbs raised against the TREM2 receptor did not 
specifically bind to the TREM2-DAP12 surface receptor. This finding is insufficient to 
determine if the receptor is expressed on the cell surface and that the tested antibodies 
were specific to this receptor. Further testing is necessary to confirm the validity of this 
model via binding effects of the aforementioned agonists.
